Aled Williams
Direttore/Membro del Consiglio presso DESTINY PHARMA PLC
Patrimonio netto: 11 113 $ in data 30/04/2024
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| William Love | M | 62 | 28 anni | |
| Debra Stephanie Barker | M | 61 | 4 anni | |
| Shaun Claydon | M | 56 | 6 anni | |
| Anthony Rudd | M | 76 | 13 anni | |
| Nigel Brooksby | M | - | 2 anni | |
| Christopher Tovey | M | 59 | 1 anni | |
| Lisa Olson | M | 63 |
Enthera Srl
 Enthera Srl BiotechnologyHealth Technology Enthera Srl develops therapeutic solutions to treat diabetes. The company was founded in 1985 by in October 2016 by Maria Gabriella Camboni, Paolo Fiorina and Francesca D'Addio and is headquartered in Milan, Italy. | - |
| James Stearns | M | - | 2 anni | |
| William Rhys-Williams | M | - | 26 anni | |
| Jim Lees | M | - | 7 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Nick Rodgers | M | 65 | 5 anni | |
| Neil Clark | M | 62 | 6 anni | |
| Huai Zheng Peng | M | 62 | 5 anni | |
| Stephanie Bewick | M | - | 2 anni | |
| Behrad Derakhshan | M | 44 |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 1 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Regno Unito | 13 | 86.67% |
| Svizzera | 1 | 6.67% |
| Italia | 1 | 6.67% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Aled Williams
- Contatti personali
